Prevalence and associated factors for thyroid dysfunction among patients on targeted therapy for cancers:A single-center study from Thailand
https://doi.org/10.15605/jafes.038.02.18
- Author:
Korawan Chawalitmongkol
1
;
Kunlatida Maneenil
2
;
Pravinwan Thungthong
3
;
Chaicharn Deerochanawong
1
Author Information
1. Division of Endocrinology and Metabolism, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
2. Division of Oncology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
3. Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
- Publication Type:Journal Article
- Keywords:
Thyroid dysfunction
- MeSH:
Tyrosine Kinase Inhibitors;
Immune Checkpoint Inhibitors;
Immunotherapy;
Neoplasms
- From:
Journal of the ASEAN Federation of Endocrine Societies
2023;38(2):77-85
- CountryPhilippines
- Language:English
-
Abstract:
Objective:This study aimed to explore the prevalence and associated factors of thyroid dysfunction among cancer patients treated with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs).
Methodology:A cross-sectional study was done in patients who received TKIs at Rajavithi Hospital in 2019. For patients treated with ICI, a retrospective chart review for patients seen in 2018 to 2019 was conducted. If there were abnormal thyroid function tests (TFT), thyroid autoantibodies were tested.
Results:There were 144 patients on TKIs with a mean age of 56.0 years. Thyroid dysfunction was found in 14.6% of patients and most had subclinical hypothyroidism (n=16, 11.1%). Imatinib (n=11, 10.8%) and sunitinib (n=4, 100%) were the 2 most common TKIs given to patients with thyroid dysfunction. Thyroid dysfunction was associated with male sex, chronic kidney disease and hepatitis B virus infection but not with previous thyroid disease and presence of thyroid autoantibodies. There were 18 patients who received ICIs. The mean age was 63.3 years. Twelve patients (66.7%) used programmed cell
death protein-1 antibody (anti-PD1), mainly nivolumab. Thyroid dysfunction was found in 50%, which occurred at a median duration of 46 days. Most patients had overt hypothyroidism and 55.6% needed levothyroxine replacement.
Conclusion:Thyroid dysfunctions from TKIs were mostly asymptomatic and mild in severity. Some types of TKIs might be associated with thyroid dysfunction. On the other hand, thyroid dysfunction from ICIs usually occurs within 6 months and requires levothyroxine replacement.
- Full text:2619-Article Text-25111-1-10-20231115.pdf
